Bracco subsidiary Blue Earth Diagnostics is directing attention to a number of presentations at the virtual annual meeting of the American Society for Radiation Oncology (ASTRO), which is being held October 23-28.
The company said that ASTRO talks will encompass the clinical use of its Axumin (fluciclovine F-18) PET radiopharmaceutical in recurrent prostate cancer, including a late-breaking abstract plenary session presentation by Emory University. In addition, information from an independent investigational study of fluciclovine F-18 PET in brain metastases will also be presented, Blue Earth said.
